Non-conventional Forms Used during Ovarian Stimulation

Section 4 - Non-conventional Forms Used during Ovarian Stimulation

Published online by Cambridge University Press: 14 April 2022

Edited by

Mohamed Aboulghar and

Botros Rizk

Show author details

Mohamed Aboulghar: Affiliation:
University of Cairo IVF Centre
Botros Rizk: Affiliation:
University of South Alabama

Book contents

Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Type: Chapter
Information: Ovarian Stimulation , pp. 189 - 222

DOI: https://doi.org/10.1017/9781316477021 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Meldrum, DR, Chang, RJ, de Ziegler, D, et al. Adjuncts for ovarian stimulation: when do we adopt “orphan indications” for approved drugs? Fertil Steril 2009;92:13–18.Google Scholar

Meldrum, DR, Wisot, A, Hamilton, F, et al. Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval. Fertil Steril 1989;51:455–459.Google Scholar

Hughes, EG, Fedorkow, DM, Daya, S, et al. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992;58:888–896.CrossRef Google Scholar PubMed

Tarlatzis, BC, Fauser, BC, Kolibianakis, EM, et al. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006;12:333–340.CrossRef Google Scholar PubMed

Lambalk, CB, Banga, FR, Huirne, JA, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update 2017;23:560–579.Google Scholar

Biljan, MM, Mahutte, NG, Dean, N, et al. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertil Steril 1998;70:1063–1069.CrossRef Google Scholar PubMed

van Heusden, AM, Fauser, BC. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception 1999;59:237–243.Google Scholar

de Ziegler, D, Jaaskelainen, AS, Brioschi, PA, Fanchin, R, Bulletti, C. Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH). Hum Reprod 1998;13:561–564.Google Scholar

Fanchin, R, Salomon, L, Castelo-Branco, A, et al. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod 2003;18:2698–2703.Google Scholar

Frattarelli, JL, Hill, MJ, McWilliams, GD, et al. A luteal estradiol protocol for expected poor-responders improves embryo number and quality. Fertil Steril 2008;89:1118–1122.Google Scholar

Daly, DC, Walters, CA, Soto-Albors, CE, Tohan, N, Riddick, DH. A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil Steril 1984;41:844–848.Google Scholar

Parsanezhad, ME, Alborzi, S, Motazedian, S, Omrani, G. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective, double-blind, placebo-controlled trial. Fertil Steril 2002;78:1001–1004.CrossRef Google Scholar

Elnashar, A, Abdelmageed, E, Fayed, M, Sharaf, M. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod 2006;21:1805–1808.Google Scholar

Keay, SD, Lenton, EA, Cooke, ID, Hull, MG, Jenkins, JM. Low-dose dexamethasone augments the ovarian response to exogenous gonadotrophins leading to a reduction in cycle cancellation rate in a standard IVF programme. Hum Reprod 2001;16:1861–1865.Google Scholar

Thurston, LM, Norgate, DP, Jonas, KC, et al. Ovarian modulators of type 1 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity and intra-follicular cortisol:cortisone ratios correlate with the clinical outcome of IVF. Hum Reprod 2003;18:1603–1612.Google Scholar

Lewicka, S, von Hagens, C, Hettinger, U, et al. Cortisol and cortisone in human follicular fluid and serum and the outcome of IVF treatment. Hum Reprod 2003;18:1613–1617.Google Scholar

Simerman, AA, Hill, DL, Grogan, TR, et al. Intrafollicular cortisol levels inversely correlate with cumulus cell lipid content as a possible energy source during oocyte meiotic resumption in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 2015;103:249–257.CrossRef Google Scholar PubMed

Palomba, S, Falbo, A, La Sala, GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 2013;120:267–276.CrossRef Google Scholar PubMed

Agrawal, R, Jacobs, H, Payne, N, Conway, G. Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovaries. Fertil Steril 2002;78:1164–1169.Google Scholar

Creanga, AA, Bradley, HM, McCormick, C, Witkop, CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol 2008;111:959–968.Google Scholar

Stadtmauer, LA, Toma, SK, Riehl, RM, Talbert, LM. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril 2001;75:505–509.Google Scholar

Tang, T, Glanville, J, Orsi, N, Barth, JH, Balen, AH. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 2006;21:1416–1425.Google Scholar

Jakubowicz, DJ, Seppala, M, Jakubowicz, S, et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:1126–1133.Google Scholar PubMed

Cermik, D, Selam, B, Taylor, HS. Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:238–243.Google Scholar

Jakubowicz, DJ, Iuorno, MJ, Jakubowicz, S, Roberts, KA, Nestler, JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:524–529.Google Scholar

De Leo, V, la Marca, A, Ditto, A, Morgante, G, Cianci, A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999;72:282–285.Google Scholar

Meldrum, DR, Scott, RT, Jr., Levy, MJ, Alper, MM, Noyes, N. Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins, and early pregnancy loss. Fertil Steril 2009;91:1963–1965.Google Scholar

Acevedo, B, Sanchez, M, Gomez, JL, et al. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles. Fertil Steril 2004;82:343–347.Google Scholar

The ganirelix dose-finding group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 1998;13:3023–3031.CrossRef Google Scholar

Kolibianakis, EM, Zikopoulos, K, Schiettecatte, J, et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod 2004;19:24902496.Google Scholar

Coomarasamy, A, Afnan, M, Cheema, D, et al. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod 2008;23:310–315.Google Scholar

Thompson, KA, LaPolt, PS, River, J, et al. Gonadotropin requirements of the developing follicle. Fertil Steril 1995;63:273–276.Google Scholar

Rubinstein, M, Marazzi, A, Polak de Fried, E. Low-dose aspirin treatment improves ovarian responsiveness, uterine and ovarian blood flow velocity, implantation, and pregnancy rates in patients undergoing in vitro fertilization: a prospective, randomized, double-blind placebo-controlled assay. Fertil Steril 1999;71:825–829.Google Scholar

Ebbesen, SM, Zachariae, R, Mehlsen, MY, et al. Stressful life events are associated with a poor in-vitro fertilization (IVF) outcome: a prospective study. Hum Reprod 2009;24:2173–2182.Google Scholar

Siristatidis, CS, Basios, G, Pergialiotis, V, Vogiatzi, P. Aspirin for in vitro fertilisation. Cochrane Database Syst Rev 2016;11:CD004832.Google Scholar

Varnagy, A, Bodis, J, Manfai, Z, et al. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. Fertil Steril 2010;93:2281–2284.Google Scholar

Bencomo, E, Perez, R, Arteaga, MF, et al. Apoptosis of cultured granulosa-lutein cells is reduced by insulin-like growth factor I and may correlate with embryo fragmentation and pregnancy rate. Fertil Steril 2006;85:474–480.Google Scholar

Harper, K, Proctor, M, Hughes, E. Growth hormone for in vitro fertilization. Cochrane Database Syst Rev 2003;3:CD000099.Google Scholar

Tesarik, J, Hazout, A, Mendoza, C. Improvement of delivery and live birth rates after ICSI in women aged >40 years by ovarian co-stimulation with growth hormone. Hum Reprod 2005;20:2536–2541.CrossRef Google Scholar PubMed

Kolibianakis, EM, Venetis, CA, Diedrich, K, Tarlatzis, BC, Griesinger, G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 2009;15:613–622.Google Scholar

Li, XL, Wang, L, Lv, F, et al. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: a systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e6443.Google Scholar

Meldrum, DR, Quaas, AM, Su, HI. Why is growth hormone underutilized for our most difficult IVF couples? Fertil Steril 2018;110:1261–1262.Google Scholar

Alvarez, C, Marti-Bonmati, L, Novella-Maestre, E, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931–2937.Google Scholar

Levin, ER, Rosen, GF, Cassidenti, DL, et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest 1998;102:1978–1985.Google Scholar

Ferraretti, AP, Gianaroli, L, Diotallevi, L, Festi, C, Trounson, A. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992;7:180–183.Google Scholar

Alvarez, C, Alonso-Muriel, I, Garcia, G, et al. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007;22:3210–3214.CrossRef Google Scholar PubMed

Vendola, KA, Zhou, J, Adesanya, OO, Weil, SJ, Bondy, CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;101:2622–2629.Google Scholar

Balasch, J, Fabregues, F, Penarrubia, J, et al. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod 2006;21:1884–1893.Google Scholar

Kim, CH, Howles, CM, Lee, HA. The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertil Steril 2011;95:679–683.Google Scholar

Garcia-Velasco, JA, Moreno, L, Pacheco, A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril 2005;84:82–87.Google Scholar

Schoolcraft, WB, Surrey, ES, Minjarez, DA, Stevens, JM, Gardner, DK. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol? Fertil Steril 2008;89:151–156.Google Scholar

Song, Y, Li, Z, Wu, X, et al. Effectiveness of the antagonist/letrozole protocol for treating poor responders undergoing in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis. Gynecol Endocrinol 2014;30:330–334.Google Scholar

Frattarelli, JL, Gerber, MD. Basal and cycle androgen levels correlate with in vitro fertilization stimulation parameters but do not predict pregnancy outcome. Fertil Steril 2006;86:51–57.Google Scholar

Barad, D, Gleicher, N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006;21:2845–2849.Google Scholar

Barad, D, Brill, H, Gleicher, N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet 2007;24:629–634.Google Scholar

Nagels, HE, Rishworth, JR, Siristatidis, CS, Kroon, B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev 2015;11:CD009749.Google Scholar

Paulson, RJ. At last, an orally active gonadotropin-releasing hormone antagonist. Fertil Steril 2019;111:30–31.Google Scholar

References

Gougeon, A. Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod 1986;1:81–87.Google Scholar

Messinis, IE, Messini, CI, Dafopoulos, K. The role of gonadotropins in the follicular phase. Ann N Y Acad Sci 2010;1205:5–11.Google Scholar

Messinis, IE. Mechanisms of follicular development: the role of gonadotrophins. In: Rizk, B, Garcia-Velasco, J, Sallam, H, Makrigiannakis, A., eds. Infertility and Assisted Reproduction. Cambridge: Cambridge University Press; 2008:3–24.Google Scholar

van Santbrink, EJ, Hop, WC, van Dessel, TJ, de Jong, FH, Fauser, BC. Decremental follicle-stimulating hormone and dominant follicle development during the normal menstrual cycle. Fertil Steril 1995;64:37–43.Google Scholar

Mihm, M, Baker, PJ, Ireland, JL, et al. Molecular evidence that growth of dominant follicles involves a reduction in follicle-stimulating hormone dependence and an increase in luteinizing hormone dependence in cattle. Biol Reprod 2006;74:1051–1059.Google Scholar

Hillier, SG. Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol 2001;179:39–46.Google Scholar

Garg, D, Tal, R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online 2016;33:15–28.Google Scholar

Erickson, GF, Shimasaki, S. The role of the oocyte in folliculogenesis. Trends Endocrinol Metab 2000;11:193–198.Google Scholar

Messinis, IE, Templeton, AA. Pituitary response to exogenous LHRH in superovulated women. J Reprod Fertil 1989;87:633–639.Google Scholar

Messinis, IE, Milingos, S, Zikopoulos, K, et al. Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone. Hum Reprod 1998;13:2415–2420.Google Scholar

Messinis, IE, Messini, CI, Anifandis, G, Garas, A, Daponte, A. Gonadotropin surge-attenuating factor: a nonsteroidal ovarian hormone controlling GnRH-induced LH secretion in the normal menstrual cycle. Vitam Horm 2018;107:263–286.Google Scholar

Cedrin-Durnerin, I, Bidart, JM, Robert, P, et al. Consequences on gonadotrophin secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for in-vitro fertilization. Hum Reprod 2000;15:1009–1014.Google Scholar

Borm, G, Mannaerts, B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000;15:1490–1498.Google Scholar PubMed

Felberbaum, RE, Albano, C, Ludwig, M, et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod 2000;15:1015–1020.Google Scholar

Propst, AM, Hill, MJ, Bates, GW, et al. Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration. Fertil Steril 2011;96:898–904.Google Scholar

Fleming, R, Lloyd, F, Herbert, M, et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod 1998;13:1788–1792.Google Scholar

Bosch, E, Vidal, C, Labarta, E, et al. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists: a randomized study. Hum Reprod 2008;23:2346–2351.Google Scholar

van Wely, M, Kwan, I, Burt, AL, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev 2011;2:CD005354.Google Scholar

Tarlatzis, B, Tavmergen, E, Szamatowicz, M, et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Hum Reprod 2006;21:90–94.CrossRef Google Scholar PubMed

NyboeAndersen, A, Humaidan, P, Fried, G, et al.; Nordic LH study group. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum Reprod 2008;23:427–434.Google Scholar

Franco, JG Jr., Baruffi, RL, Oliveira, JB, et al. Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study. Reprod Biol Endocrinol 2009;7:58.Google Scholar

Kolibianakis, EM, Kalogeropoulou, L, Griesinger, G, et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update 2007;13:445–452.Google Scholar

Al-Inany, HG, Abou-Setta, AM, Aboulghar, MA, Mansour, RT, Serour, GI. Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with recombinant FSH: a meta-analysis. Gynecol Endocrinol 2009;25:372–378.Google Scholar

Mochtar, MH, Danhof, NA, Ayeleke, RO, Van der Veen, F, van Wely, M. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. Cochrane Database Syst Rev 2017;5:CD005070.Google Scholar

Thuesen, LL, Loft, A, Egeberg, AN, et al. A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization. Hum Reprod 2012;27:3074–3084.Google Scholar

Requena, A, Cruz, M, Ruiz, FJ, García-Velasco, JA. Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin. Reprod Biol Endocrinol 2014;12:10.Google Scholar

Messinis, IE, Templeton, AA. Disparate effects of endogenous and exogenous oestradiol on luteal phase function in women. J Reprod Fertil 1987;79:549–554.Google Scholar

Martins, WP, Ferriani, RA, Navarro, PA, Nastri, CO. GnRH agonist during luteal phase in women undergoing assisted reproductive techniques: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol 2016;47:144–151.Google Scholar

van der Linden, M, Buckingham, K, Farquhar, C, Kremer, JA, Metwally, M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2015;7:CD009154.Google Scholar

Mochtar, MH, Van der Veen, F, Ziech, M, van Wely, M. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007;2:CD005070.Google Scholar

Matorras, R, Prieto, B, Exposito, A, et al. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online 2009;19:879–887.Google Scholar

Bosch, E, Labarta, E, Crespo, J, et al. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril 2011;95:1031–1036.Google Scholar

König, TE, van der Houwen, LE, Overbeek, A, et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Hum Reprod 2013;28:2804–2812.Google Scholar

Hill, MJ, Levens, ED, Levy, G, et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril 2012;97:1108.e1–1114.e1.Google Scholar

Lehert, P, Kolibianakis, EM, Venetis, CA, et al. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol 2014;12:17.CrossRef Google Scholar PubMed

Humaidan, P, Chin, W, Rogoff, D, et al.; ESPART Study Investigators. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod 2017;32:544–555.CrossRef Google Scholar PubMed

Revelli, A, Chiado’, A, Guidetti, D, et al. Outcome of in vitro fertilization in patients with proven poor ovarian responsiveness after early vs. mid-follicular LH exposure: a prospective, randomized, controlled study. J Assist Reprod Genet 2012;29:869–875.Google Scholar

Messinis, IE, Bergh, T, Wide, L. The importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in women with anovulatory infertility. Fertil Steril 1988;50:31–35.Google Scholar

Lewit, N, Kol, S. The low responder female IVF patient with hypogonadotropic hypogonadism: do not give up! Fertil Steril 2000;74:401–402.Google Scholar

Pandurangi, M, Tamizharasi, M, Reddy, NS. Pregnancy outcome of assisted reproductive technology cycle in patients with hypogonadotropic hypogonadism. J Hum Reprod Sci 2015;8:146–150.Google Scholar

Durnerin, CI, Erb, K, Fleming, R, et al.; Luveris Pretreatment Group. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod 2008;23:421–426.Google Scholar

Sullivan, MW, Stewart-Akers, A, Krasnow, JS, Berga, SL, Zeleznik, AJ. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab 1999;84:228–232.Google Scholar

Yong, EL, Baird, DT, Yates, R, Reichert, LE Jr., Hillier, SG. Hormonal regulation of the growth and steroidogenic function of human granulosa cells. J Clin Endocrinol Metab 1992;74:842–849.Google Scholar

Loumaye, E, Engrand, P, Shoham, Z, Hillier, SG, Baird, DT. Clinical evidence for an LH ‘ceiling’ effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod 2003;18:314–322.Google Scholar

Baird, DT. Is there a place for different isoforms of FSH in clinical medicine? IV. The clinician’s point of view. Hum Reprod 2001;16:1316–1318.Google Scholar

References

The Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril 2008;90:S219–S225.Google Scholar

Bulun, SE, Adashi, EY. The physiology and pathology of the female reproductive axis. In: Melmed, S, Polonsky, KS, Larsen, PR, Kronenberg, HM, eds. Williams Textbook of Endocrinology, 13th ed. Philadelphia: Elsevier Health Sciences; 2015:590–663.Google Scholar

Fevold, HL. Synergism of follicle stimulating and luteinizing hormones in producing estrogen secretion. Endocrinology 1941;28:33–36.Google Scholar

Richards, JS. Hormonal control of gene expression in the ovary. Endocr Rev 1994;15:725–751.Google Scholar

Erickson, GF, Magoffin, DA, Dyer, CA, Hofeditz, C. The ovarian androgen producing cells: a review of structure/function relationships. Endocr Rev 1985;6:371–399.Google Scholar

Angelopoulos, N, Goula, A, Tolis, G. The role of luteinizing hormone activity in controlled ovarian stimulation. J Endocrinol Invest 2005;28:79–88.Google Scholar

European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 1998;83:1507–1514.Google Scholar

Lunenfeld, B. Historical perspectives in gonadotrophin therapy. Hum Reprod Update 2004;10:453–467.Google Scholar

Rowe, PJ, Comhaire, FH, Hargreave, TB, et al. WHO Manual for the Standardized Investigation and Diagnosis of the Infertile Couple. Cambridge: Cambridge University Press; 1993.Google Scholar

Shoham, Z, Conway, GS, Patel, A, Jacobs, HS. Polycystic ovaries in patients with hypogonadotropic hypogonadism: similarity of ovarian response to gonadotropin stimulation in patients with polycystic ovarian syndrome. Fertil Steril 1992;58:37–45.Google Scholar

Schachter, M, Balen, AH, Patel, A, Jacobs, HS. Hypogonadotropic patients with ultrasonographically detected polycystic ovaries: endocrine response to pulsatile gonadotropin-releasing hormone. Gynecol Endocrinol 1996;10:327–335.Google Scholar

Muasher, SJ, Abdallah, RT, Hubayter, ZR. Optimal stimulation protocols for in vitro fertilization. Fertil Steril 2006;86:267–273.Google Scholar

The Practice Committee of the American Society for Reproductive Medicine, Birmingham, Alabama. Gonadotropin preparations: past, present and future perspectives. Fertil Steril 2008;90(5 Suppl):S13–S20.Google Scholar

Al-Inany, H, Aboulghar, MA, Mansour, RT, Proctor, M. Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception. Hum Reprod 2006;21:569–570.Google Scholar

Bordewijk, EM, Mol, F, van der Veen, F, Van Wely, M. Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis. Hum Reprod Open 2019;2019(3):hoz008.Google Scholar

The Practice Committee of the American Society for Reproductive Medicine. Use of exogenous gonadotropins in anovulatory women: a technical bulletin. Fertil Steril 2008;90(5 Suppl):S7–S12.Google Scholar

Filicori, M, Cognigni, GE, Samara, A, et al. The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update 2002;8:543–557.Google Scholar

Krause, BT, Ohlinger, R, Haase, A. Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review. Biologics 2009;3:337–347.Google Scholar

Shoham, Z, Balen, A, Patel, A, Jacobs, HS. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients. Fertil Steril 1991;56:1048–1053.Google Scholar

O’Dea, L, the US Recombinant Human LH Study Group. Recombinant LH in support of recombinant FSH in female hypogonadotropic hypogonadism-evidence of threshold effect. Fertil Steril 2000;74(Suppl 1):S36.Google Scholar

Hagen, CP, Sørensen, K, Anderson, RA, Juul, A. Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist. Fertil Steril 2012;98(5):1326–1330.Google Scholar

Sönmezer, M, Özmen, B, Atabekoglu, CS, et al. Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism. J Assist Reprod Genet 2012;29(7):597–602.Google Scholar

Messinis, IE. Ovulation induction: a mini review. Hum Reprod 2005;20:2688–2697.Google Scholar

Van der Linden, M, Buckingham, K, Farquhar, C, Kremer, JA, Metwally, M. Luteal phase support in assisted reproduction cycles. Hum Reprod Update 2012;18(5):473.Google Scholar

Aboulghar, M. Luteal support in reproduction: when, what and how? Curr Opin Obstet Gynecol 2009;21:279–284.Google Scholar

Kaufmann, R, Dunn, R, Vaughn, T, et al. Recombinant human luteinizing hormone, lutropin alfa, for the induction of follicular development and pregnancy in profoundly gonadotrophin-deficient women. Clin Endocrinol (Oxf) 2007;67:563–569.Google Scholar

Shoham, Z, Smith, H, Yeko, T, et al. Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, double-blind, placebo-controlled, proof-of-efficacy study. Clin Endocrinol (Oxf) 2008;69:471–478.Google Scholar

Awwad, JT, Farra, C, Mitri, F, et al. Split daily recombinant human LH dose in hypogonadotrophic hypogonadism: a nonrandomized controlled pilot study. Reprod Biomed Online 2013;26(1):88–92.Google Scholar

le Cotonnec, JY, Loumaye, E, Porchet, H, Beltrami, V, Munafo, A. Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. Fertil Steril 1998;69(2):201–209.Google Scholar

Balasch, J, Fábregues, F, Carmona, F, Casamitjana, R, Tena-Sempere, M. Ovarian luteinizing hormone priming preceding follicle-stimulating hormone stimulation: clinical and endocrine effects in women with long-term hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2009;94:2367–2373.Google Scholar

Fluker, MR, Urman, B, Mackinnon, M, et al. Exogenous gonadotropin therapy in World Health Organization groups I and II ovulatory disorders. Obstet Gynecol 1994;83:189–196.Google Scholar

Tadokoro, N, Vollenhoven, B, Clark, S, et al. Cumulative pregnancy rates in couples with anovulatory infertility compared with unexplained infertility in an ovulation induction programme. Hum Reprod 1997;12:1939–1944.Google Scholar

Kumbak, B, Kahraman, S. Women with hypogonadotropic hypogonadism: cycle characteristics and results of assisted reproductive techniques. Acta Obstet Gynecol Scand 2006;85:1453–1457.Google Scholar

Ghaffari, F, Arabipoor, A, Lankarani, NB, Etminan, Z, Tehraninejad, ES. Assisted reproductive technique outcomes in hypogonadotropic hypogonadism women. Ann Saudi Med 2013;33(3):235–240.Google Scholar

Pandurangi, M, Tamizharasi, M, Reddy, NS. Pregnancy outcome of assisted reproductive technology cycle in patients with hypogonadotropic hypogonadism. J Hum Reprod Sci 2015;8(3):146–150.Google Scholar

Yilmaz, S, Ozgu-Erdinc, AS, Yumusak, O, et al. The reproductive outcome of women with hypogonadotropic hypogonadism undergoing in vitro fertilization. Syst Biol Reprod Med 2015;61(4):228–232.Google Scholar

Mumusoglu, S, Ata, B, Turan, V, et al. Does pituitary suppression affect live birth rate in women with congenital hypogonadotrophic hypogonadism undergoing intra-cytoplasmic sperm injection? A multicenter cohort study. Gynecol Endocrinol 2017;33(9):728–732.Google Scholar

Cecchino, GN, Canillas, GM, Cruz, M, García-Velasco, JA. Impact of hypogonadotropic hypogonadism on ovarian reserve and response. J Assist Reprod Genet 2019;36(11):2379–2384.Google Scholar

Kuroda, K, Ezoe, K, Kato, K, et al. Infertility treatment strategy involving combined freeze‐all embryos and single vitrified‐warmed embryo transfer during hormonal replacement cycle for in vitro fertilization of women with hypogonadotropic hypogonadism. J Obstet Gynaecol Res 2018;44(5):922–928.Google Scholar

Klemetti, R, Sevon, T, Gissler, M, Hemm, E. Complications of IVF and ovulation induction. Hum Reprod 2005;20:3293–3300.Google Scholar

Aboulghar, M. Symposium: Update on prediction and management of OHSS. Prevention of OHSS. Reprod Biomed Online 2009;19:33–42.Google Scholar

The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2008;90(5 Suppl):S188–S193.Google Scholar

Mathur, R, Kailasam, C, Jenkins, J. Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome. Hum Fertil 2007;10:75–85.Google Scholar

Letterie, GS, Coddington, CC, Collins, RL, Merriam, GR. Ovulation induction using s.c. pulsatile gonadotrophin-releasing hormone: effectiveness of different pulse frequencies. Hum Reprod 1996;11:19–22.Google Scholar

Homburg, R, Eshel, A, Armar, NA, et al. One hundred pregnancies after treatment with pulsatile luteinizing hormone releasing hormone to induce ovulation. Br Med J 1989;298:809–812.Google Scholar

Braat, DD, Ayalon, D, Blunt, SM, et al. Pregnancy outcome in luteinizing hormone-releasing hormone induced cycles: a multicentre study. Gynecol Endocrinol 1989;3:35–44.Google Scholar

Martin, KA, Hall, JE, Adams, JM, Crowley, WF Jr. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea. J Clin Endocrinol Metab 1993;77(1):125–129.Google Scholar

Mattle, V, Leyendecker, G, Wildt, L. Side effects of pulsatile GnRH therapy for induction of ovulation. Expert Rev Endocrinol Metab 2008;3:535–538.Google Scholar

Filicori, M, Flamigni, C, Dellai, P, et al. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab 1994;79(4):1215–1220.Google Scholar

Hall, R, Manski-Nankervis, J, Goni, N, Davies, MC, Conway, GS. Fertility outcomes in women with hypopituitarism. Clin Endocrinol 2006;65:71–74.Google Scholar

Hull, KL, Harvey, S. Growth hormone: roles in female reproduction. J Endocrinol 2001;168:1–23.Google Scholar

Park, JK, Murphy, AA, Bordeaux, BL, Dominguez, CE, Session, DR. Ovulation induction in a poor responder with panhypopituitarism: a case report and review of the literature. Gynecol Endocrinol 2007;23:82–86.Google Scholar

Homburg, R, West, C, Torresani, T, Jacobs, HS. Cotreatment with human growth hormone and gonadotropins for induction of ovulation: a controlled clinical trial. Fertil Steril 1990;53:254–260.Google Scholar

Giampietro, A, Milardi, D, Bianchi, A, et al. The effect of treatment with growth hormone on fertility outcome in eugonadal women with growth hormone deficiency: report of four cases and review of the literature. Fertil Steril 2009;91(3):930.e7–930.e11.Google Scholar

Daniel, A, Ezzat, S, Greenblatt, E. Adjuvant growth hormone for ovulation induction with gonadotropins in the treatment of a woman with hypopituitarism. Case Rep Endocrinol 2012;20:12.Google Scholar

Salle, A, Klein, M, Pascal-Vigneron, V, et al. Successful pregnancy and birth after sequential cotreatment with growth hormone and gonadotropins in a woman with panhypopituitarism: a new treatment protocol. Fertil Steril 2000;74:1248–1250.Google Scholar

Harper, K, Proctor, M, Hughes, E. Growth hormone for in vitro fertilization. Cochrane Database Syst Rev 2003;3:CD000099.Google Scholar

Jacobs, HS, Shoham, Z, Schachter, M, et al. Cotreatment with growth-hormone and gonadotropin for ovulation induction in hypogonadotropic patients-a prospective, randomized, placebo-controlled, dose-response study. Fertil Steril 1995;64(5):917–923.Google Scholar

Curran, AJ, Peacey, SR, Shalet, SM. Is maternal growth hormone essential for a normal pregnancy? Eur J Endocrinol 1998;139:54–58.Google Scholar

Menashe, Y, Sack, J, Mashiach, S. Spontaneous pregnancies in two women with Laron-type dwarfism: are growth hormone and circulating insulin-like growth factor mandatory for induction of ovulation? Hum Reprod 1991;6:670–671.Google Scholar

Voutetakis, A, Sertedaki, A, Livadas, S, et al. Ovulation induction and successful pregnancy outcome in two patients with Prop1 gene mutations. Fertil Steril 2004;82:454–457.Google Scholar

Yildirim, M, Noyan, V, Tiras, MB. Estrogen-progestagen pre-treatment before HMG induction in hypogonadotropic patients. Int J Gynaecol Obstet 2000;71:249–250.Google Scholar

Hayashi, M, Tomobe, K, Hoshimoto, K, Ohkura, T. Successful pregnancy following gonadotropin therapy in a patient with hypogonadotropic hypogonadism resulting from craniopharyngioma. Int J Clin Pract 2002;56:149–151.Google Scholar

Toumba, M, Sergis, A, Kanaris, C, Skordis, N. Endocrine complications in patients with thalassaemia major. Pediatr Endocrinol Rev 2007;5:642–648.Google Scholar

Chatterjee, R, Bajoria, R. Critical appraisal of growth retardation and pubertal disturbances in thalassemia. Ann N Y Acad Sci 2010;1202(1):100–114.Google Scholar

Poggi, M, Sorrentino, F, Pugliese, P, et al. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. Ann Hematol 2016;95(5):757–763.Google Scholar

Pafumi, C, Farina, M, Pernicone, G, et al. At term pregnancies in transfusion-dependent beta-thalassemic women. Clin Exp Obstet Gynecol 2000;27:185–187.Google Scholar

Skordis, N, Christou, S, Koliou, M, Pavlides, N, Angastiniotis, M. Fertility in female patients with thalassemia. J Pediatr Endocrinol Metab 1998;11(Suppl 3):935–943.Google Scholar

Karagiorga-Lagana, M. Fertility in thalassemia: the Greek experience. J Pediatr Endocrinol Metab 1998;11(Suppl 3):945–951.Google Scholar

Cunningham, MJ, Macklin, EA, Muraca, G, Neufeld, EJ. Successful pregnancy in thalassemia major women in the Thalassemia Clinical Research Network. Pediatr Res 2004;55:294A.Google Scholar

Tuck, SM. Fertility and pregnancy in thalassemia major. Ann N Y Acad Sci 2005;1054:300–307.Google Scholar

Bajoria, R, Chatterjee, R. Current perspectives of fertility and pregnancy in thalassemia. Hemoglobin 2009;33(Suppl 1):S131–S135.Google Scholar

Origa, R, Piga, A, Quarta, G, et al. Pregnancy and β-thalassemia: an Italian multicenter experience. Haematologica 2010;95(3):376–381.Google Scholar

Dungan, HM, Clifton, DK, Steiner, RA. Minireview: kisspeptin neurons as central processors in the regulation of gonadotropin-releasing hormone secretion. Endocrinology 2006;147:1154–1158.Google Scholar

Lee, JH, Miele, ME, Hicks, DJ, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996;88:1731–1737.Google Scholar

Tena-Sempere, M. Kisspeptin signaling in the brain: recent developments and future challenges. Mol Cell Endocrinol 2010;314:164–169.Google Scholar

Reynolds, RM, Logie, JJ, Roseweir, AK, McKnight, AJ, Millar, RP. A role for kisspeptins in pregnancy: facts and speculations. Reproduction 2009;138:1–7.Google Scholar

Thompson, EL, Patterson, M, Murphy, KG, et al. Central and peripheral administration of kisspeptin-10 stimulates the hypothalamic-pituitary-gonadal axis. J Neuroendocrinol 2004;16:850–858.Google Scholar

Dhillo, WS, Chaudhri, OB, Thompson, EL, et al. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women. J Clin Endocrinol Metab 2007;92:3958–3966.Google Scholar

Roa, J, Aguilar, E, Dieguez, C, Pinilla, L, Tena-Sempere, M. New frontiers in kisspeptin/GPR54 physiology as fundamental gatekeepers of reproductive function. Front Neuroendocrinol 2008;29:48–69.Google Scholar

Dekel, N. Master regulators of female infertility. N Engl J Med 2009;361:718–719.Google Scholar

Fan, HY, Liu, Z, Shimada, M, et al. MAPK3/1 (ERK1/2) in ovarian granulosa cells are essential for female fertility. Science 2009;324:938–941.Google Scholar

Xekouki, P, Tolis, G. Ovulation induction for hypogonadotropic hypogonadism. In: Aboulghar, M, Rizk, B, eds. Ovarian Stimulation. Cambridge: Cambridge University Press; 2011:162–172.Google Scholar

Book contents

Section 4 - Non-conventional Forms Used during Ovarian Stimulation

Summary

Access options

References

References

References

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive